Bridging translation by improving preclinical study design in AKI

Journal of the American Society of Nephrology

Volumn 26, Issue 12, 2015, Pages 2905-2916

  De Caestecker, Mark ^a   Humphreys, Ben D ^b   Liu, Kathleen D ^c   Fissell, William H ^a   Cerda, Jorge ^d   Nolin, Thomas D ^e   Askenazi, David ^f   Mour, Girish ^e   Harrell, Frank E ^g   Pullen, Nick ^h   Okusa, Mark D ⁱ   Faubel, Sarah ^j  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f University of Alabama at Birmingham   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

ⁱ UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BICARBONATE; ERYTHROPOIETIN; CONTRAST MEDIUM; SCAVENGER;

ACUTE KIDNEY FAILURE; CLINICAL EVALUATION; CLINICAL RESEARCH; CONTRAST INDUCED NEPHROPATHY; EVIDENCE BASED PRACTICE; HEALTH CARE PLANNING; HUMAN; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; REVIEW; STUDY DESIGN; TREATMENT RESPONSE; ACUTE KIDNEY INJURY; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; METHODOLOGY; STANDARDS; TRANSLATIONAL RESEARCH;

ACETYLCYSTEINE; ACUTE KIDNEY INJURY; ANIMALS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; FREE RADICAL SCAVENGERS; HUMANS; RESEARCH DESIGN; SODIUM BICARBONATE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84958238052     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015070832     Document Type: Review

References (107)

1. Rewa O, Bagshaw SM: Acute kidney injuryepidemiology, outcomes and economics. Nat Rev Nephrol 10: 193-207, 2014
2. Bellomo R, Kellum JA, Ronco C: Acute kidney injury. Lancet 380: 756-766, 2012
3. Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, Liu KD, Mehta RL, Pannu N, Van Biesen W, Vanholder R: Acute kidney injury: An increasing global concern. Lancet 382: 170-179, 2013
4. Coca SG, Singanamala S, Parikh CR: Chronic kidney disease after acute kidney injury: A systematic review and metaanalysis. Kidney Int 81: 442-448, 2012
5. Chawla LS, Kimmel PL: Acute kidney injury and chronic kidney disease: An integrated clinical syndrome. Kidney Int 82: 516-524, 2012
6. Wald R, Quinn RR, Adhikari NK, Burns KE, Friedrich JO, Garg AX, Harel Z, HladunewichMA, Luo J,MamdaniM, Perl J, Ray JG; University of Toronto Acute Kidney Injury Research Group: Risk of chronic dialysis and death following acute kidney injury. Am J Med 125: 585-593, 2012
7. Bucaloiu ID, Kirchner HL, Norfolk ER, Hartle JE 2nd, Perkins RM: Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int 81: 477-485, 2012
8. Wu VC, Huang TM, Lai CF, Shiao CC, Lin YF, Chu TS,Wu PC, Chao CT,Wang JY, Kao TW, YoungGH, Tsai PR, TsaiHB, Wang CL, Wu MS, Chiang WC, Tsai IJ, Hu FC, Lin SL, Chen YM, Tsai TJ, Ko WJ, Wu KD: Acuteon-chronic kidney injury at hospital discharge is associated with long-termdialysis and mortality. Kidney Int 80: 1222-1230, 2011
9. Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE: The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 79: 1361-1369, 2011
10. Cerda J, Liu KD, Cruz DN, Jaber BL, Koyner JL, Heung M, Okusa MD, Faubel S; AKI Advisory Group of the American Society of Nephrology: Promoting kidney function recovery in patients with AKI requiring RRT. Clin J Am Soc Nephrol 10: 1859-1857, 2015
11. Hsu CY, Ordoñez JD, Chertow GM, Fan D, McCulloch CE, Go AS: The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 74: 101-107, 2008
12. Molitoris BA, Okusa MD, Palevsky PM, Kimmel PL, Star RA: Designing clinical trials in acute kidney injury. Clin J Am Soc Nephrol 7: 842-843, 2012
13. Palevsky PM,Molitoris BA,OkusaMD, Levin A, Waikar SS, Wald R, Chertow GM, Murray PT, Parikh CR, Shaw AD, Go AS, Faubel SG, Kellum JA, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene T, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA: Design of clinical trials in acute kidney injury: Report from an NIDDK workshop on trial methodology. Clin J Am Soc Nephrol 7: 844-850, 2012
14. Sanz AB, Sanchez-Niño MD, Martín-Cleary C, Ortiz A, Ramos AM: Progress in the development of animal models of acute kidney injury and its impact on drug discovery. Expert Opin Drug Discov 8: 879-895, 2013
15. Heyman SN, Rosen S, Rosenberger C: Animal models of renal dysfunction: Acute kidney injury. Expert Opin Drug Discov 4: 629-641, 2009
16. Doi K, Leelahavanichkul A, Yuen PS, Star RA: Animal models of sepsis and sepsisinduced kidney injury. J Clin Invest 119: 2868-2878, 2009
17. Ortiz A, Sanchez-Niño MD, Izquierdo MC, Martin-Cleary C, Garcia-Bermejo L,Moreno JA, Ruiz-Ortega M, Draibe J, Cruzado JM, Garcia-Gonzalez MA, Lopez-Novoa JM, Soler MJ, Sanz AB; Red de Investigacion Renal (REDINREN) and Consorcio Madrileño para investigación del fracaso renal agudo (CIFRA): Translational value of animal models of kidney failure. Eur J Pharmacol 759: 205-220, 2015
18. Begley CG, Ellis LM: Drug development: Raise standards for preclinical cancer research. Nature 483: 531-533, 2012
19. Prinz F, Schlange T, Asadullah K: Believe it or not: How much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10: 712, 2011
20. Hartshorne JK, Schachner A: Tracking replicability as a method of post-publication open evaluation. Front ComputNeurosci 6: 8, 2012
21. Vasilevsky NA, Brush MH, Paddock H, Ponting L, Tripathy SJ, Larocca GM, Haendel MA: On the reproducibility of science: Unique identification of research resources in the biomedical literature. PeerJ 1: e148, 2013
22. Glasziou P, Meats E, Heneghan C, Shepperd S: What is missing from descriptions of treatment in trials and reviews? BMJ 336: 1472-1474, 2008
23. Pullen N, Birch CL, Douglas GJ, Hussain Q, Pruimboom-Brees I, Walley RJ: The translational challenge in the development of new and effective therapies for endometriosis: A review of confidence from published preclinical efficacy studies. Hum Reprod Update 17: 791-802, 2011
24. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD: A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490: 187-191, 2012
25. Collins FS, Tabak LA: Policy: NIH plans to enhance reproducibility. Nature 505: 612-613, 2014
26. McNutt M: Journals unite for reproducibility. Science 346: 679, 2014
27. Anonymous: Journals unite for reproducibility. Nature 515: 7, 2014
28. Kilkenny C, BrowneWJ, Cuthill IC, Emerson M, Altman DG: Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol 8: e1000412, 2010
29. Manolagas SC,KronenbergHM: Reproducibility of results in preclinical studies: A perspective from the bone field. J Bone Miner Res 29: 2131-2140, 2014
30. Macleod MR, Fisher M, O'Collins V, Sena ES, Dirnagl U, Bath PM, Buchan A, van der Worp HB, Traystman R, Minematsu K, Donnan GA, Howells DW: Good laboratory practice: Preventing introduction of bias at the bench. Stroke 40: e50-e52, 2009
31. Mobley A, Linder SK, Braeuer R, Ellis LM, Zwelling L: A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic. PLoS One 8: e63221, 2013
32. Hackam DG, Redelmeier DA: Translation of research evidence from animals to humans. JAMA 296: 1731-1732, 2006
33. Ioannidis JP: Extrapolating from animals to humans. Sci Transl Med 4: 151ps15, 2012
34. Hess KR: Statistical design considerations in animal studies published recently in cancer research. Cancer Res 71: 625, 2011
35. Ritskes-Hoitinga M, Leenaars M, Avey M, RoversM, Scholten R: Systematic reviews of preclinical animal studies can make significant contributions to health care and more transparent translational medicine. Cochrane Database Syst Rev 3: ED000078, 2014
36. Perrin S: Preclinical research: Make mouse studies work. Nature 507: 423-425, 2014
37. Freedman LP, Cockburn IM, Simcoe TS: The economics of reproducibility in preclinical research. PLoS Biol 13: e1002165, 2015
38. Fedorov V, Mannino F, Zhang R: Consequences of dichotomization. Pharm Stat 8: 50-61, 2009
39. Aurelio A, Durante A: Contrast-induced nephropathy in percutaneous coronary interventions: Pathogenesis, risk factors, outcome, prevention and treatment. Cardiology 128: 62-72, 2014
40. Weisbord SD, Gallagher M, Kaufman J, Cass A, Parikh CR, Chertow GM, Shunk KA, McCullough PA, Fine MJ, Mor MK, Lew RA, Huang GD, Conner TA, Brophy MT, Lee J, Soliva S, Palevsky PM: Prevention of contrast-induced AKI: A review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. Clin J Am Soc Nephrol 8: 1618-1631, 2013
41. ACT Investigators: Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: Main results from the randomized Acetylcysteine for Contrastinduced nephropathy Trial (ACT). Circulation 124: 1250-1259, 2011
42. Burgess WP, Walker PJ: Mechanisms of contrast-induced nephropathy reduction for saline (NaCl) and sodium bicarbonate (NaHCO3). BioMed Res Int 2014: 510385, 2014
43. Merten GJ, BurgessWP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, Norton HJ, Kennedy TP: Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 291: 2328-2334, 2004
44. Atkins JL: Effect of sodium bicarbonate preloading on ischemic renal failure. Nephron 44: 70-74, 1986
45. Sporer H, Lang F,Oberleithner H, Greger R, Deetjen P: Inefficacy of bicarbonate infusions on the course of postischaemic acute renal failure in the rat. Eur J Clin Invest 11: 311-315, 1981
46. Ladwig M, Flemming B, Seeliger E, Sargsyan L, Persson PB: Renal effects of bicarbonate versus saline infusion for iso- and lowosmolar contrast media in rats. Invest Radiol 46: 672-677, 2011
47. Efrati S, Berman S, Ilgiyeav I, Siman-Tov Y, Averbukh Z, Weissgarten J: Differential effects of N-acetylcysteine, theophylline or bicarbonate on contrast-induced rat renal vasoconstriction. Am J Nephrol 29: 181-191, 2009
48. Barlak A, Akar H, Yenicerioglu Y, Yenisey C, Meteoglu I, Yilmaz O: Effect of sodium bicarbonate in an experimental model of radiocontrast nephropathy. Ren Fail 32: 992-999, 2010
49. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343: 180-184, 2000
50. Baliga R, Ueda N, Walker PD, Shah SV: Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 29: 465-477, 1997
51. Yoshioka T, Fogo A, Beckman JK: Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 41: 1008-1015, 1992
52. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr.: Radiocontrast mediuminduced declines in renal function: A role for oxygen free radicals. Am J Physiol 258: F115-F120, 1990
53. Parvez Z, RahmanMA,Moncada R: Contrast media-induced lipid peroxidation in the rat kidney. Invest Radiol 24: 697-702, 1989
54. Salom MG, Ramírez P, Carbonell LF, López Conesa E, Cartagena J, Quesada T, Parrilla P, Fenoy FJ: Protective effect of N-acetyl-Lcysteine on the renal failure induced by inferior vena cava occlusion. Transplantation 65: 1315-1321, 1998
55. DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R: N-acetyl cysteine ameliorates ischemic renal failure. Am J Physiol 272: F292-F298, 1997
56. Bartnicki P, Kowalczyk M, Rysz J: The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection. Med Sci Monit 19: 599-605, 2013
57. Tasanarong A, Duangchana S, Sumransurp S, Homvises B, SatdhabudhaO: Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinase-associated lipocalin in patients undergoing cardiac surgery: A randomized, double-blind controlled trial. BMC Nephrol 14: 136, 2013
58. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, Han S, Kim JH, Na KY: Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: A pilot study. Am J Nephrol 30: 253-260, 2009
59. Sølling C, Christensen AT, Krag S, Frøkiaer J, Wogensen L, Krog J, Tønnesen EK: Erythropoietin administration is associated with short-term improvement in glomerular filtration rate after ischemia-reperfusion injury. Acta Anaesthesiol Scand 55: 185-195, 2011
60. Souza AC, Volpini RA, ShimizuMH, Sanches TR, Camara NO, Semedo P, Rodrigues CE, Seguro AC, Andrade L: Erythropoietin prevents sepsis-related acute kidney injury in rats by inhibiting NF-kB and upregulating endothelial nitric oxide synthase. Am J Physiol Renal Physiol 302: F1045-F1054, 2012
61. Ishii Y, Sawada T, Murakami T, Sakuraoka Y, Shiraki T, Shimizu A, Kubota K, Fuchinoue S, Teraoka S: Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a non-human primate model. Nephrol Dial Transplant 26: 1157-1162, 2011
62. Spandou E, Tsouchnikas I, Karkavelas G, Dounousi E, Simeonidou C, Guiba-Tziampiri O, Tsakiris D: Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant 21: 330-336, 2006
63. Mohamed HE, El-Swefy SE, Mohamed RH, Ghanim AM: Effect of erythropoietin therapy on the progression of cisplatin induced renal injury in rats. Exp Toxicol Pathol 65: 197-203, 2013
64. Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NS, Yaqoob MM, Thiemermann C: Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 22: 63-69, 2004
65. Wang Z, Schley G, Türkoglu G, Burzlaff N, Amann KU, Willam C, Eckardt KU, Bernhardt WM: The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to EPO treatment. Nephrol Dial Transplant 27: 929-936, 2012
66. Matejková S, Scheuerle A, Wagner F, McCook O, Matallo J, Gröger M, Seifritz A, Stahl B, Vcelar B, Calzia E, Georgieff M, Möller P, Schelzig H, Radermacher P, Simon F: Carbamylated erythropoietin-FC fusion protein and recombinant human erythropoietin during porcine kidney ischemia/reperfusion injury. Intensive Care Med 39: 497-510, 2013
67. Liu X, Zhang T, Xia W, Wang Y, Ma K: Recombinant human erythropoietin pretreatment alleviates renal glomerular injury induced by cardiopulmonary bypass by reducing transient receptor potential channel 6-nuclear factor of activated T-cells pathway activation. J Thorac Cardiovasc Surg 146: 681-687, 2013
68. Coldewey SM, Khan AI, Kapoor A, Collino M, Rogazzo M, Brines M, Cerami A, Hall P, Sheaff M, Kieswich JE, Yaqoob MM, Patel NS, Thiemermann C: Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the b-common receptor. Kidney Int 84: 482-490, 2013
69. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, DiazD,Gomez D, Hand C, Coleman T, Cerami A: Erythropoietin mediates tissue protection through an erythropoietin and common betasubunit heteroreceptor. Proc Natl Acad Sci U S A 101: 14907-14912, 2004
70. Stojanovic V, Vuckovic N, Spasojevic S, BarišicN,Doronjski A, Zikic D:Theinfluence of EPO and hypothermia on the kidneys of rats after perinatal asphyxia. Pediatr Nephrol 27: 139-144, 2012
71. Eshraghi-Jazi F, Nematbakhsh M, Pezeshki Z, Nasri H, Talebi A, Safari T, Mansouri A, Mazaheri S, Ashrafi F: Sex differences in protective effect of recombinant human erythropoietin against cisplatin-induced nephrotoxicity in rats. Iran J Kidney Dis 7: 383-389, 2013
72. Vaziri ND, Zhou XJ, Liao SY: Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 266[3 Pt 2]: F360-F366, 1994
73. Bagnis C, Beaufils H, Jacquiaud C, Adabra Y, Jouanneau C, Le Nahour G, Jaudon MC, Bourbouze R, Jacobs C, Deray G: Erythropoietin enhances recovery after cisplatininduced acute renal failure in the rat. Nephrol Dial Transplant 16: 932-938, 2001
74. Salahudeen AK, Haider N, Jenkins J, Joshi M, Patel H, Huang H, Yang M, Zhe H: Antiapoptotic properties of erythropoiesiss timulating proteins in models of cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol 294: F1354-F1365, 2008
75. Bi B, Guo J, Marlier A, Lin SR, Cantley LG: Erythropoietin expands a stromal cell population that can mediate renoprotection. Am J Physiol Renal Physiol 295: F1017-F1022, 2008
76. Lee DW, Kwak IS, Lee SB, Song SH, Seong EY, Yang BY, Lee MY, Sol MY: Posttreatment effects of erythropoietin and nordihydroguaiaretic acid on recovery from cisplatin-induced acute renal failure in the rat. J Korean Med Sci 24(Suppl): S170-S175, 2009
77. Choi DE, Jeong JY, Lim BJ, Lee KW, Shin YT, Na KR: Pretreatment with darbepoetin attenuates renal injury in a rat model of cisplatin-induced nephrotoxicity. Korean J Intern Med 24(3): 238-246, 2009
78. Rjiba-Touati K, Boussema IA, Belarbia A, Achour A, Bacha H: Protective effect of recombinant human erythropoietin against cisplatin-induced oxidative stress and nephrotoxicity in rat kidney. Int J Toxicol 30(5): 510-517, 2011
79. Kong D, Zhuo L, Gao C, Shi S, Wang N, Huang Z, Li W, Hao L: Erythropoietin protects against cisplatin-induced nephrotoxicity by attenuating endoplasmic reticulum stress-induced apoptosis. J Nephrol 26: 219-227, 2013
80. Yang CW, Li C, Jung JY, Shin SJ, Choi BS, Lim SW, Sun BK, Kim YS, Kim J, Chang YS, Bang BK: Preconditioning with erythropoietin protects against subsequent ischemiareperfusion injury in rat kidney. FASEB J 17: 1754-1755, 2003
81. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM: Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15: 2115-2124, 2004
82. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC: Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 69(10): 1806-1813, 2006
83. Esposito C, Pertile E,Grosjean F, Castoldi F, Diliberto R, Serpieri N, Arra M, Villa L, Mangione F, Esposito V, Migotto C, Valentino R, Dal Canton A: The improvement of ischemia/reperfusion injury by erythropoetin is not mediated through bone marrow cell recruitment in rats. Transplant Proc 41(4): 1113-1115, 2009
84. Moeini M, Nematbakhsh M, Fazilati M, Talebi A, PilehvarianAA,Azarkish F, Eshraghi-Jazi F, Pezeshki Z: Protective role of recombinant human erythropoietin in kidney and lung injury following renal bilateral ischemia-reperfusion in rat model. Int J Prev Med 4: 648-655, 2013
85. Gobe GC, Bennett NC, West M, Colditz P, Brown L, Vesey DA, JohnsonDW: Increased progression to kidney fibrosis after erythropoietin is used as a treatment for acute kidney injury. Am J Physiol Renal Physiol 306: F681-F692, 2014
86. Gardner DS, Welham SJ, Dunford LJ, McCulloch TA, Hodi Z, Sleeman P,O'Sullivan S, Devonald MA: Remote conditioning or erythropoietin before surgery primes kidneys to clear ischemia-reperfusion-damaged cells: A renoprotective mechanism? Am J Physiol Renal Physiol 306: F873-F884, 2014
87. Shen S, Jin Y, Li W, Liu X, Zhang T, Xia W, Wang Y, Ma K: Recombinant human erythropoietin pretreatment attenuates acute renal tubular injury against ischemiareperfusion by restoring transient receptor potential channel-6 expression and function in collecting ducts. Crit Care Med 42: e663-e672, 2014
88. Sølling C, Christensen AT, Krag S, Frøkiaer J, Wogensen L, Krog J, Tønnesen EK: Erythropoietin administration is associated with short-term improvement in glomerular filtration rate after ischemia-reperfusion injury. Acta Anaesthesiol Scand 55(2): 185-195, 2011
89. Matejková S, Scheuerle A, Wagner F, McCook O, Matallo J, Gröger M, Seifritz A, Stahl B, Vcelar B, Calzia E, Georgieff M, Möller P, Schelzig H, Radermacher P, Simon F: Carbamylated erythropoietin-FC fusion protein and recombinant human erythropoietin during porcine kidney ischemia/reperfusion injury. Intensive Care Med 39(3): 497-510, 2013
90. Wang G,Huang H, Wu H,Wu C, Xu Y, Wang L, Liu X, Wang C, Shen Y, Li D, Jing H: Erythropoietin attenuates cardiopulmonary bypass-induced renal inflammatory injury by inhibiting nuclear factor-kB p65 expression. Eur J Pharmacol 689: 154-159, 2012
91. Stojanovic V, Vuckovic N, Spasojevic S, Barišic N,Doronjski A, Zikic D: Theinfluence of EPO and hypothermia on the kidneys of rats after perinatal asphyxia. Pediatr Nephrol 27: 139-144, 2012
92. Goldfarb M, Rosenberger C, Ahuva S, Rosen S, Heyman SN: A role for erythropoietin in the attenuation of radiocontrastinduced acute renal failure in rats. Ren Fail 28(4): 345-350, 2006
93. Mitra A, Bansal S, Wang W, Falk S, Zolty E, Schrier RW: Erythropoietin ameliorates renal dysfunction during endotoxaemia. Nephrol Dial Transplant 22: 2349-2353, 2007
94. Eren Z, Coban J, Ekinci ID, Kaspar C, Kantarci G: Evaluation of the effects of a high dose of erythropoietin-beta on early endotoxemia using a rat model. Adv Clin Exp Med 21: 321-329, 2012
95. Coldewey SM1, Khan AI, Kapoor A, Collino M, Rogazzo M, Brines M, Cerami A, Hall P, Sheaff M, Kieswich JE, Yaqoob MM, Patel NS, Thiemermann C: Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the b-common receptor. Kidney Int 84(3): 482-490, 2013
96. Stoyanoff TR, Todaro JS, Aguirre MV, ZimmermannMC, Brandan NC:Amelioration of lipopolysaccharide-induced acute kidney injury by erythropoietin: involvement of mitochondria-regulated apoptosis. Toxicology 318: 13-21, 2014
97. Kaynar K, Aliyazioglu R, Ersoz S, Ulusoy S, Al S, Ozkan G, Cansiz M: Role of erythropoietin in prevention of amikacininduced nephropathy. J Nephrol 25: 744-749, 2012
98. Lin X,Qu S, HuM, Jiang C: Protective effect of erythropoietin on renal injury induced by acute exhaustive exercise in the rat. Int J Sports Med 31: 847-853, 2010
99. Yang FL, Subeq YM, Chiu YH, Lee RP, Lee CJ, Hsu BG: Recombinant human erythropoietin reduces rhabdomyolysisinduced acute renal failure in rats. Injury 43: 367-373, 2012
100. Dardashti A, Ederoth P, Algotsson L, Brondén B, Grins E, LarssonM, Nozohoor S, Zinko G, Bjursten H: Erythropoietin and protection of renal function in cardiac surgery (the EPRICS Trial). Anesthesiology 121: 582-590, 2014
101. KimJH, Shim JK, Song JW, Song Y, KimHB, Kwak YL: Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety. Crit Care 17: R254, 2013
102. Tasanarong A, Duangchana S, Sumransurp S,Homvises B, SatdhabudhaO: Prophylaxis with erythropoietin versus placebo reduces acute kidney injury andneutrophilgelatinaseassociated lipocalin in patients undergoing cardiac surgery: a randomized, doubleblind controlled trial. BMC Nephrol 14: 136, 2013
103. de Seigneux S, Ponte B, Weiss L, Pugin J, Romand JA, Martin PY, Saudan P: Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. BMC Nephrol 13: 132, 2012
104. Endre ZH1, Walker RJ, Pickering JW, Shaw GM, FramptonCM,Henderson SJ,Hutchison R, Mehrtens JE, Robinson JM, Schollum JB, Westhuyzen J, Celi LA, McGinley RJ, Campbell IJ, George PM: Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 77(11): 1020-1030, 2010
105. Oh SW, Chin HJ, Chae DW, Na KY: Erythropoietin improves long-termoutcomes in patients with acute kidney injury after coronary artery bypass grafting. J Korean Med Sci 27(5):506-511, 2012
106. Sureshkumar KK, Hussain SM, Ko TY, Thai NL, Marcus RJ: Effect of high-dose erythropoietin on graft function after kidney transplantation: A randomized, doubleblind clinical trial. Clin J Am Soc Nephrol 7: 1498-1506, 2012
107. Coupes B, de Freitas DG, Roberts SA, Read I, Riad H, Brenchley PE, Picton ML: rhErythropoietin-b as a tissue protective agent in kidney transplantation: A pilot randomized controlled trial. BMC Res Notes 8: 21, 2015